China’s Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
Summary
The resulting first-in-class database, named PolypharmDB, is a library of clinically assessed molecules and their polypharmacological profiles that can be used to identify repurposing opportunities for drug candidates. Leveraging PolypharmDB and MatchMaker, Cyclicas scientists investigated both human targets as well as viral proteins with potential therapeutic relevance for COVID-19 in rapid fashion. CCAA is committed to building a cross-border ecosystem between China and Canada, and promoting international exchanges and collaboration between Chinese and Canadian entrepreneurs through joint investment, entrepreneurial mentorship, and connecting cross-border resources. With a world-class team with deep roots in industry and a first-in-class integrated drug discovery platform, Cyclica will spark a surge of innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies. By doing more with AI, Cyclica will revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.